CIK 0001088856 · Large accelerated filer
CORCEPT THERAPEUTICS INC
Sign in to watch- Ticker
- CORT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770487658
- Phone
- 650.688.8803
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,067,988
- in 15 filings, $36.6M under 10b5-1 plans
Net −$41,067,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Mokari Atabak Chief Financial Officer | Grant or award | +554 | 9,536 | ||
| 2024-03-01 | Swisher Daniel N JR Director | Option exercise 10b5-1 | +2,200 | $5.86 | $13K | 2,200 |
| 2024-03-01 | Swisher Daniel N JR Director | Sale 10b5-1 | −2,200 | $23.59 | $52K | 0 |
| 2024-03-01 | Swisher Daniel N JR Director | Option exercise · Stock option (right to buy) 10b5-1 | −2,200 | 8,950 | ||
| 2024-03-01 | Robb Gary Charles Chief Business Officer | Shares withheld for taxes | −656 | $24.06 | $16K | 18,809 |
| 2024-03-01 | Robb Gary Charles Chief Business Officer | Grant or award | +697 | $24.06 | $17K | 19,506 |
| 2024-03-01 | Robb Gary Charles Chief Business Officer | Grant or award | +697 | 20,203 | ||
| 2024-02-16 | Lyon Joseph Douglas Chief Accounting Officer | Option exercise 10b5-1 | +1,000 | $11.35 | $11K | 7,774 |
| 2024-02-16 | Lyon Joseph Douglas Chief Accounting Officer | Sale 10b5-1 | −1,000 | $26.00 | $26K | 6,774 |
| 2024-02-16 | Lyon Joseph Douglas Chief Accounting Officer | Option exercise · Stock option (right to buy) 10b5-1 | −1,000 | 43,167 | ||
| 2024-02-16 | Maduck Sean See Remarks | Option exercise 10b5-1 | +12,226 | $3.29 | $40K | 86,681 |
| 2024-02-16 | Maduck Sean See Remarks | Option exercise 10b5-1 | +14,842 | $3.88 | $58K | 101,523 |
| 2024-02-16 | Maduck Sean See Remarks | Sale 10b5-1 | −27,068 | $25.97 | $703K | 74,455 |
| 2024-02-16 | Maduck Sean See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | −12,226 | 0 | ||
| 2024-02-16 | Maduck Sean See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | −14,842 | 135,158 | ||
| 2024-02-15 | Maduck Sean See Remarks | Option exercise 10b5-1 | +4,760 | $3.29 | $16K | 79,215 |
| 2024-02-15 | Maduck Sean See Remarks | Sale 10b5-1 | −4,760 | $25.00 | $119K | 74,455 |
| 2024-02-15 | Maduck Sean See Remarks | Option exercise · Stock option (right to buy) 10b5-1 | −4,760 | 12,226 | ||
| 2024-02-09 | Maduck Sean See Remarks | Grant or award · Stock option (right to buy) | +200,000 | 200,000 | ||
| 2024-02-09 | BELANOFF JOSEPH K Chief Executive Officer | Grant or award · Stock option (right to buy) | +500,000 | 500,000 |
Page 42 of 61 · 1,220 trades